Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03075553 · ClinicalTrials.gov registry record · Phase 2
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03075553: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT03075553 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03075553, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-05-17 |
| Est. Completion | 2019-05-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03075553
The ClinicalTrials.gov registry entry for NCT03075553 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03075553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03075553 about?
NCT03075553 is a clinical study titled "Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma". This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain c...
What is the current status of trial NCT03075553?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2017-05-17. Estimated completion is 2019-05-29.
What interventions are being tested in trial NCT03075553?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03075553?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.